• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RGD 修饰的聚（D，L-乳酸）纳米粒增强冬凌草甲素的肿瘤靶向性。

RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin.

机构信息

School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.

出版信息

Int J Nanomedicine. 2012;7:211-9. doi: 10.2147/IJN.S27581. Epub 2012 Jan 9.

DOI:10.2147/IJN.S27581
PMID:22275836
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3263413/
Abstract

OBJECTIVE

The purpose of this study was to develop an active targeting strategy to improve the therapeutic antitumor efficacy of oridonin (ORI), the main active ingredient in the medicinal herb Rabdosia rubescens.

METHODS

A modified spontaneous emulsification solvent diffusion method was used to prepare the ORI-loaded atactic poly(D,L-lactic acid) nanoparticles (ORI-PLA-NPs). Surface cross-linking with the peptide Arg-Gly-Asp (RGD) further modified the ORI-PLA-NPs, generating ORI-PLA-RGD-NPs. The NPs were characterized and release experiments were performed in vitro. The pharmacokinetics, tissue distribution, and antitumor activity of the NPs were studied in mice bearing hepatocarcinoma 22 (H22)-derived tumors.

RESULTS

The ORI-PLA-NPs and ORI-PLA-RGD-NPs were smooth, sphere-like, and relatively uniform in size. The RGD surface modification slightly increased the mean particle size (95.8 nm for ORI-PLA-NPs versus 105.2 nm for ORI-PLA-RGD-NPs) and considerably altered the surface electrical property (-10.19 mV for ORI-PLA-NPs versus -21.95 mV for ORI-PLA-RGD-NPs), but it had no obvious influence on ORI loading (8.23% ± 0.35% for ORI-PLA-NPs versus 8.02% ± 0.38% for ORI-PLA-RGD-NPs), entrapment efficiency (28.86% ± 0.93% for ORI-PLA-NPs versus 28.24% ± 0.81% for ORI-PLA-RGD-NPs), or the release of ORI. The pharmacokinetic properties of free ORI were improved by encapsulation in NPs, as shown by increased area under the concentration-time curve (11.89 ± 0.35 μg·mL(-1) · h for ORI solution versus 22.03 ± 0.01 μg · mL(-1) · h for ORI-PLA-RGD-NPs) and prolonged mean retention time (2.03 ± 0.09 hours for ORI solution versus 8.68 ± 0.66 hours for ORI-PLA-RGD-NPs). In the tissue distribution study, more ORI targeted tumor tissue in the mice treated with ORI-PLA-RGD-NPs than with ORI-PLA-NPs or ORI solution. Consistent with these observations, ORI-PLA-RGD-NPs showed greater antitumor efficacy than ORI-PLA-RGD-NPs or ORI solution, as reflected by the decreased tumor growth and the prolonged survival time of mice bearing H22 tumors.

CONCLUSION

The tumor-targeting efficiency and subsequent antitumor efficacy of ORI is increased by incorporation into ORI-PLA-RGD-NPs.

摘要

目的

本研究旨在开发一种主动靶向策略，以提高来源于草药冬凌草的主要活性成分冬凌草甲素（ORI）的治疗抗肿瘤疗效。

方法

采用改良的自发乳化溶剂扩散法制备 ORI 载无规聚（D，L-乳酸）纳米粒（ORI-PLA-NPs）。用肽 Arg-Gly-Asp（RGD）进行表面交联进一步修饰 ORI-PLA-NPs，生成 ORI-PLA-RGD-NPs。对 NPs 进行了表征，并进行了体外释放实验。研究了载药纳米粒在荷肝癌 22（H22）肿瘤小鼠中的药代动力学、组织分布和抗肿瘤活性。

结果

ORI-PLA-NPs 和 ORI-PLA-RGD-NPs 呈光滑、球形且大小相对均匀。RGD 表面修饰略微增加了平均粒径（ORI-PLA-NPs 为 95.8nm，ORI-PLA-RGD-NPs 为 105.2nm），并显著改变了表面电荷性质（ORI-PLA-NPs 为-10.19mV，ORI-PLA-RGD-NPs 为-21.95mV），但对 ORI 载药量（ORI-PLA-NPs 为 8.23%±0.35%，ORI-PLA-RGD-NPs 为 8.02%±0.38%）、包封率（ORI-PLA-NPs 为 28.86%±0.93%，ORI-PLA-RGD-NPs 为 28.24%±0.81%）或 ORI 的释放没有明显影响。ORI 被包封在 NPs 中后，其药代动力学性质得到改善，表现为曲线下面积增加（ORI 溶液为 11.89±0.35μg·mL（-1）·h，ORI-PLA-RGD-NPs 为 22.03±0.01μg·mL（-1）·h）和平均滞留时间延长（ORI 溶液为 2.03±0.09 小时，ORI-PLA-RGD-NPs 为 8.68±0.66 小时）。在组织分布研究中，与 ORI-PLA-NPs 或 ORI 溶液相比，荷瘤小鼠用 ORI-PLA-RGD-NPs 治疗后，更多的 ORI 靶向肿瘤组织。与这些观察结果一致，与 ORI-PLA-RGD-NPs 或 ORI 溶液相比，ORI-PLA-RGD-NPs 显示出更高的抗肿瘤疗效，表现为肿瘤生长减少和荷 H22 肿瘤小鼠的生存时间延长。

结论

将 ORI 包封入 ORI-PLA-RGD-NPs 可提高 ORI 的肿瘤靶向效率和随后的抗肿瘤疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/46c73040a98e/ijn-7-211f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/5c1a9567ab2d/ijn-7-211f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/b0bd3d394840/ijn-7-211f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/a2929782bc0a/ijn-7-211f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/24c1ce311930/ijn-7-211f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/0e7d54e2a329/ijn-7-211f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/8881f94fb6e6/ijn-7-211f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/2d86255c4e74/ijn-7-211f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/8572572252db/ijn-7-211f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/46c73040a98e/ijn-7-211f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/5c1a9567ab2d/ijn-7-211f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/b0bd3d394840/ijn-7-211f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/a2929782bc0a/ijn-7-211f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/24c1ce311930/ijn-7-211f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/0e7d54e2a329/ijn-7-211f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/8881f94fb6e6/ijn-7-211f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/2d86255c4e74/ijn-7-211f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/8572572252db/ijn-7-211f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c70/3263413/46c73040a98e/ijn-7-211f9.jpg

相似文献

1
RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin.RGD 修饰的聚（D，L-乳酸）纳米粒增强冬凌草甲素的肿瘤靶向性。
Int J Nanomedicine. 2012;7:211-9. doi: 10.2147/IJN.S27581. Epub 2012 Jan 9.
2
Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo.载有冬凌草甲素的聚（D，L-乳酸）纳米粒的体内外研究。
Int J Biol Macromol. 2007 Jan 30;40(2):153-8. doi: 10.1016/j.ijbiomac.2006.07.001. Epub 2006 Aug 8.
3
RGD-conjugated PLA-PLL nanoparticles targeting to Bacp-37 breast cancer xenografts in vivo.靶向体内Bacp-37乳腺癌异种移植瘤的RGD偶联聚乳酸-聚赖氨酸纳米颗粒。
J Nanosci Nanotechnol. 2011 Dec;11(12):10760-4. doi: 10.1166/jnn.2011.3945.
4
Antitumor activity of docetaxel-loaded polymeric nanoparticles fabricated by Shirasu porous glass membrane-emulsification technique.载多西紫杉醇聚合物纳米粒的抗肿瘤活性的制备工艺 Shirasu 多孔玻璃膜乳化技术。
Int J Nanomedicine. 2013;8:2641-52. doi: 10.2147/IJN.S48214. Epub 2013 Jul 29.
5
In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.载奥定宁长循环纳米结构脂质载体的体内外评价。
Int J Biol Macromol. 2012 Apr 1;50(3):523-9. doi: 10.1016/j.ijbiomac.2012.01.024. Epub 2012 Jan 24.
6
Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma.载有冬凌草甲素的聚（ε-己内酯）-聚（环氧乙烷）-聚（ε-己内酯）共聚物纳米粒：制备、表征及其对移植性肝癌小鼠的抗肿瘤活性
J Drug Target. 2008 Jul;16(6):479-85. doi: 10.1080/10611860802200938.
7
Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.半乳糖化壳聚糖纳米粒用于冬凌草甲素肝靶向递药
Int J Pharm. 2012 Oct 15;436(1-2):379-86. doi: 10.1016/j.ijpharm.2012.06.039. Epub 2012 Jun 23.
8
GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.GE11肽偶联硒纳米颗粒用于表皮生长因子受体（EGFR）靶向冬凌草甲素递送，通过抑制EGFR介导的PI3K/AKT和Ras/Raf/MEK/ERK信号通路来增强抗癌疗效。
Drug Deliv. 2017 Nov;24(1):1549-1564. doi: 10.1080/10717544.2017.1386729.
9
The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy.设计并合成响应氧化还原的氧化苦参碱聚合物前药胶束制剂用于有效的胃癌治疗。
J Mater Chem B. 2021 Apr 7;9(13):3068-3078. doi: 10.1039/d1tb00127b. Epub 2021 Mar 22.
10
Discovery and in vivo evaluation of novel RGD-modified lipid-polymer hybrid nanoparticles for targeted drug delivery.新型RGD修饰的脂质-聚合物杂化纳米粒用于靶向药物递送的发现与体内评价
Int J Mol Sci. 2014 Sep 29;15(10):17565-76. doi: 10.3390/ijms151017565.

引用本文的文献

1
Isodon rubescens research literature based on Web of Science database for visual analysis: A review.基于Web of Science数据库的冬凌草研究文献可视化分析：综述
Medicine (Baltimore). 2025 May 2;104(18):e41945. doi: 10.1097/MD.0000000000041945.
2
Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.增强癌症治疗效果：用于冬凌草甲素的先进纳米载体递送系统
Front Pharmacol. 2024 Dec 3;15:1476739. doi: 10.3389/fphar.2024.1476739. eCollection 2024.
3
Oridonin from : An emerging potential in cancer therapy - A comprehensive review.

本文引用的文献

1
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents.聚丙交酯-乙交酯纳米粒用于抗癌药物的控制释放。
Int J Nanomedicine. 2011;6:877-95. doi: 10.2147/IJN.S18905. Epub 2011 May 27.
2
Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice.冬凌草甲素纳米混悬液增强 SMMC-7721 细胞和 H22 荷瘤小鼠的抗肿瘤疗效。
Colloids Surf B Biointerfaces. 2011 Oct 15;87(2):319-25. doi: 10.1016/j.colsurfb.2011.05.037. Epub 2011 May 27.
3
Recent advances in PEG-PLA block copolymer nanoparticles.
冬凌草甲素的研究进展：癌症治疗中的新兴潜力——综述
Food Sci Nutr. 2024 Feb 1;12(5):3046-3067. doi: 10.1002/fsn3.3986. eCollection 2024 May.
4
Smart Targeted Delivery Systems for Enhancing Antitumor Therapy of Active Ingredients in Traditional Chinese Medicine.用于增强中药活性成分抗肿瘤治疗的智能靶向递送系统。
Molecules. 2023 Aug 8;28(16):5955. doi: 10.3390/molecules28165955.
5
Preparation and evaluation of the anti-cancer properties of RGD-modified curcumin-loaded chitosan/perfluorohexane nanocapsules .RGD修饰的载姜黄素壳聚糖/全氟己烷纳米胶囊的制备及其抗癌性能评价
Heliyon. 2022 Jul 11;8(7):e09931. doi: 10.1016/j.heliyon.2022.e09931. eCollection 2022 Jul.
6
Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway.载有冬凌草甲素的纳米颗粒通过调节ROS相关的Nrf2信号通路抑制乳腺癌进展。
Front Bioeng Biotechnol. 2021 Apr 7;9:600579. doi: 10.3389/fbioe.2021.600579. eCollection 2021.
7
Solubility and Bioavailability Enhancement of Oridonin: A Review.冬凌草甲素增溶和生物利用度提高的研究进展：综述
Molecules. 2020 Jan 14;25(2):332. doi: 10.3390/molecules25020332.
8
Polymeric Co-Delivery Systems in Cancer Treatment: An Overview on Component Drugs' Dosage Ratio Effect.聚合物共递药系统在癌症治疗中的应用：组分药物剂量比例效应概述。
Molecules. 2019 Mar 15;24(6):1035. doi: 10.3390/molecules24061035.
9
Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway.土槿皮乙酸和紫杉醇协同作用，通过活性氧介导的PTEN/PI3K/Akt信号通路调控来抑制胃癌细胞的增殖。
Oncotarget. 2016 Nov 8;7(45):72990-73002. doi: 10.18632/oncotarget.12166.
10
Discovery and development of natural product oridonin-inspired anticancer agents.天然产物冬凌草甲素启发的抗癌药物的发现与开发。
Eur J Med Chem. 2016 Oct 21;122:102-117. doi: 10.1016/j.ejmech.2016.06.015. Epub 2016 Jun 13.
聚乙二醇-聚乳酸嵌段共聚物纳米粒的最新进展。
Int J Nanomedicine. 2010 Nov 26;5:1057-65. doi: 10.2147/IJN.S14912.
4
Aliphatic polyester polymer stars: synthesis, properties and applications in biomedicine and nanotechnology.脂肪族聚酯聚合物星：在生物医学和纳米技术中的合成、性能和应用。
Chem Soc Rev. 2011 Mar;40(3):1761-76. doi: 10.1039/c0cs00091d. Epub 2010 Nov 16.
5
Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells.蛋白质组学鉴定冬凌草甲素在 HepG2 细胞中抗癌活性相关的蛋白。
Phytomedicine. 2011 Jan 15;18(2-3):163-9. doi: 10.1016/j.phymed.2010.06.011. Epub 2010 Aug 17.
6
Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells.冬凌草甲素通过激活ERK-p53凋亡途径和抑制PTK-Ras-Raf-JNK生存途径，诱导小鼠纤维肉瘤L929细胞发生G2/M期阻滞和凋亡。
Arch Biochem Biophys. 2009 Oct 1;490(1):70-5. doi: 10.1016/j.abb.2009.08.011. Epub 2009 Aug 20.
7
Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin.冬凌草甲素自微乳化药物传递系统的优化及在体肠吸收研究
Int J Pharm. 2009 Jan 5;365(1-2):136-42. doi: 10.1016/j.ijpharm.2008.08.009. Epub 2008 Aug 20.
8
Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma.载有冬凌草甲素的聚（ε-己内酯）-聚（环氧乙烷）-聚（ε-己内酯）共聚物纳米粒：制备、表征及其对移植性肝癌小鼠的抗肿瘤活性
J Drug Target. 2008 Jul;16(6):479-85. doi: 10.1080/10611860802200938.
9
Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.冬凌草甲素纳米混悬液的药代动力学及组织分布研究
Int J Pharm. 2008 May 1;355(1-2):321-7. doi: 10.1016/j.ijpharm.2007.12.016. Epub 2007 Dec 23.
10
Preparation and evaluation of self-microemulsifying drug delivery system of oridonin.冬凌草甲素自微乳化药物传递系统的制备与评价
Int J Pharm. 2008 May 1;355(1-2):269-76. doi: 10.1016/j.ijpharm.2007.12.026. Epub 2007 Dec 27.